News for Knight Therapeutics Inc. (GUD.TO)

Knight Therapeutics (KHTRF) has secured a revolving credit arrangement with National Bank of Canada, drawing C$60 million to partially finance its acquisition o

**media[646563,646564]**

New 8-count bottles now available through major retail pharmaciesARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and l

25,000 U.S. adults per year claim reimbursement for medical costs associated with babesiosis v. CDC estimates of 2,000A full 45 percent of persistent babesiosis

Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand.Gross profit increased 124% to $90.3 thousand. WASHINGTON, May 15, 2025 (GLOBE N

**media[627626]**

Endo Inc's diverse portfolio and recent strategic moves position it for potential growth amidst industry challenges.Financial restructuring and a planned merge

Knight Therapeutics Inc. (OTCPK:KHTRF) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsSamira Sakhia – President and Chief...

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Knight Therapeuti

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NGUD.TO - Knight Therapeutics IncQ1 2025 Knight Therapeutics Inc Earnings CallMay 08, 2025 / 12

**media[618146]**

Knight Therapeutics (KHTRF) has taken over complete commercial operations for ONICIT IV and announced the relaunch of the product in Brazil and Mexico through i

**media[611518]**

WASHINGTON, April 10, 2025 (GLOBE NEWSWIRE) -- Geoff Dow, infectious disease product development expert and chief executive officer of 60 Degrees Pharmaceutic

MONTREAL, March 28, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Gl…

FY 2024 net product revenues increased 140% to $607.6 thousand.FY 2024 gross profit increased $443.8 thousand from ($221 thousand) to $222.8 thousand. WASHINGT

**media[579350]**

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced to…

Knight Therapeutics Inc (TSX:GUD) is set to release its Q4 2024 earnings on Mar 20, 2025. The consensus estimate for Q4 2024 revenue is $86.18 million, and the